Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BX Other blood glucose lowering drugs, excl. insulins
A10BX02 Repaglinide
D00594 Repaglinide (JAN/USP/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Glucose Control Agents, Other
Repaglinide
D00594 Repaglinide (JAN/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D00594 Repaglinide (JAN/USP/INN)
Drug groups [BR:br08330]
Antidiabetic agent
DG01508 Sulfonylurea receptor agonist
DG01735 Glinide
D00594 Repaglinide
DG02044 Hypoglycemic agent
DG01735 Glinide
D00594 Repaglinide
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
D00594 Repaglinide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00594 Repaglinide
Drug classes [BR:br08332]
Antidiabetic agent
DG01735 Glinide
D00594 Repaglinide
DG02044 Hypoglycemic agent
D00594 Repaglinide
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
ABCC8(SUR1)/KCNJ11(KIR6.2)
D00594 Repaglinide (JAN/USP/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00594
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D00594
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00594
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00594